European Committee for Treatment and Research in Multiple Sclerosis Congress (ECTRIMS)

In the first of its kind ARISE study, treatment with dimethyl fumarate resulted in more than 80% reduction in risk of first demyelinating event relative to placebo.

The neurologist in the Mellen Center for Multiple Sclerosis Treatment and Research at Cleveland Clinic, shares more on his late breaker presentation from the 38th ECTRIMS conference. [WATCH TIME: 4 minutes]

After preliminary data suggested that humoral response may be delayed among those vaccinated against COVID-19 treated with ocrelizumab, new data from the ECTRIMS Congress suggest a third booster dose can revive such response safely.

Data from the CLARIFY-MS study showed significant improvements in Multiple Sclerosis Quality of Life-54 physical and mental composite scores, with consistent safety and tolerability among patients with MS.

The professor of public health and sports science at Aarhus University shared his perspective on the potential to modify multiple sclerosis disease progression with lifestyle interventions. [WATCH TIME: 2 minutes]

Dose-dependent reductions in neurofilament light were observed at week 144 in both those who continued treatment from the double-blind period and those who switched from placebo.

The senior consultant for the department of neurology at the National Neuroscience Institute shared more details about his presentation that he gave at the 38th ECTRIMS Congress. [WATCH TIME: 6 minutes]

Using a cohort of more than 2000 pregnancies, the data showed an extremely rare number of major congenital anomalies while on ocrelizumab, as most patients underwent live birth with no issue.

The senior consultant for the department of neurology at the National Neuroscience Institute discussed his thoughts on improvements in the MS field in relation to this year's ECTRIMS conference. [WATCH TIME: 4 minutes]

Using phenotypically “extreme” MS groups, annualized brain volume loss was higher in progressors vs non-progressors and was predicted by baseline GFAP and NfL levels.

In a small real-world cohort, annualized relapse rates were reduced for patients with multiple sclerosis who switched to cladribine (Mavenclad; EMD Serono) from ocrelizumab (Ocrevus; Genentech), natalizumab (Tysabri; Biogen), and alemtuzumab (Lemtrada; Sanofi Genzyme).

The favorable annualized relapse rates for fingolimod over interferon beta-1a observed in the 2-year core phase continued in a 5-year open-label extension.

Over a median of 73.5 weeks of follow-up time, zero adjudicated relapses were observed for those with AQP4+ NMOSD on ravulizumab.

The senior consultant for the department of neurology at the National Neuroscience Institute shares what he looks forward to at this year's ECTRIMS conference. [WATCH TIME: 2 minutes]

Among 43 cycles that achieved pregnancy, investigators observed decreases of annualized relapse rates from 0.26 to 0.09.

The 2022 Congress of the European Committee for Treatment and Research in Multiple Sclerosis will take place in Amsterdam, the Netherlands, from October 26 to 28, and is expected to feature almost 250 presenters.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of the European Committee for Treatment and Research in Multiple Sclerosis.

The director of the Mellen Center for MS Treatment and Research at Cleveland Clinic discussed the possibility of using multiple DMTs to combat the effects of MS. [WATCH TIME: 3 minutes]

The professor of neurology at the NYU Grossman School of Medicine provided his thoughts on the most notable strides within the multiple sclerosis field in the past year. [WATCH TIME: 3 minutes]

The staff member at the Mellen Center for Multiple Sclerosis discussed reasons why patients may stop treatment, as well as strategies for maintaining communication with the healthcare team in the event of discontinuation. [WATCH TIME: 5 minutes]

The NeurologyLive staff compiled highlights from our discussions with experts in one convenient location, following ECTRIMS 2021.

Discussing a 6-week, virtual program conducted over Zoom, the founder of First Coast Integrative Medicine, spoke on the use of telehealth and future research efforts for integrative medicine in MS. [WATCH TIME: 3 minutes]

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Stephen Krieger, MD.

Deborah Miller, PhD, commented on strategies to maintain patient-provider communication following the discontinuation of disease-modifying therapies in MS.

The founder of First Coast Integrative Medicine spoke on a 6-week virtual program that introduced IM modalities, including guided journaling, nutrition, and yoga. [WATCH TIME: 3 minutes]

Ashish Pradhan, MD, the executive director and disease area lead for MS and NMOSD, Genentech, offered insight on a number of presentations at the 2021 ECTRIMS Congress.

Discussing this year’s virtual ECTRIMS conference, the Zimmermann Professor of Neurology and Neurological Sciences, and Pediatrics at Stanford University provided his opinion on recent developments in the MS field. [WATCH TIME: 3 minutes]

The Zimmermann Professor of Neurology and Neurological Sciences, and Pediatrics at Stanford University discussed the treatment’s potential in the multiple sclerosis space, where there are other competing drugs with similar safety profiles. [WATCH TIME: 4 minutes]

Megan Weigel, DNP, APRN-C, APHN-C, MSCN, discussed findings from a study of integrative medicine via a virtual, 6-week workshop, which produced varied results.

After showing potential remyelination effects, the director of the Multiple Sclerosis Center at Ochsner Health offered her perspective on the latest data for ATA188 in progressive MS. [WATCH TIME: 4 minutes]